Cargando…

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation

The majority of patients with acute myeloid leukemia (AML) with the NPM1 mutation achieve remission with intensive chemotherapy. However, many patients subsequently relapse, which occurs frequently within the first 2–3 years after therapy, while late relapse after more than 10 years is rare and can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braune, Jan, Rieger, Kathrin, Blau, Olga, Keller, Ulrich, Bullinger, Lars, Krönke, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812588/ https://www.ncbi.nlm.nih.gov/pubmed/36619478 http://dx.doi.org/10.1155/2022/3317936

Ejemplares similares

Bilateral Conjunctival Infiltration as an Extramedullary Relapse of AML
por: Mozaheb, Zahra, et al.
Publicado: (2018)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective study
por: Xie, Ning, et al.
Publicado: (2019)

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation
por: Hong, Ji-Yun, et al.
Publicado: (2020)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
por: Dukka, Srivasavi, et al.
Publicado: (2015)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

P1613: SINGLE-CELL ANALYSIS FOLLOWING SARS-COV-2 MRNA VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Tranter, E., et al.
Publicado: (2022)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT
por: Bohl, S, et al.
Publicado: (2016)

Granulocytic Sarcoma of the Uterus: A Rare Presentation of Extramedullary Relapse of AML and Importance of MRI
por: Ucar, Murat, et al.
Publicado: (2014)

Unusual isolated extramedullary relapse of acute lymphoblastic leukemia in the breast despite complete donor hematopoietic chimerism after allogeneic hematopoietic stem cell transplantation
por: Sung, Pack Hyun, et al.
Publicado: (2018)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
por: Yilmaz, Asu Fergun, et al.
Publicado: (2017)

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report
por: Wang, Jin, et al.
Publicado: (2014)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Kumode, Takahiro, et al.
Publicado: (2020)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings
por: Urano, Misugi, et al.
Publicado: (2019)

Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature
por: Kothari, Shalin, et al.
Publicado: (2013)

Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib
por: Kondo, Toshinori, et al.
Publicado: (2014)

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
por: Wang, Dongmei, et al.
Publicado: (2018)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

Extramedullary Gastric Relapse at the Time of Bone Marrow Relapse of Acute Lymphoblastic Leukemia after Allogeneic Bone Marrow Transplantation
por: Ikeuchi, Kazuhiko, et al.
Publicado: (2017)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

Sclerosing Extramedullary Hematopoietic Tumor
por: Deniz, Kemal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_317jo03hs6s0dj7jc3feg8bam2